Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.
Biomarkers
Immunogenicity
Pharmacokinetics (PK)
Cell-Based Assays
Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.
Biosimilars
Gene Therapy
Antibody Drug Conjugates (ADCs)
Immuno-oncology
Co-Hosted with Bioanalysis Zone
With the question “should we qualify or validate an exploratory biomarker assay before sample testing?” in mind, BioAgilytix’s Dr. Afshin Safavi reviews and discusses the latest scientific and regulatory considerations for the analytical validation of assays for fluid-based biomarkers used in the qualification of drug development tools (DDTs).
Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.
Quick links to our latest content offerings:
November 14, 2019Supporting CAR-T Therapies, Part 1: Innovation to Overcome Bioanalytical Challenges
November 6, 2019BioAgilytix Team Q&A: Meet Tatjana Ackermann, Quality Assurance Auditor
November 4, 2019BioAgilytix Announces Acquisition of Boston-Based Clinical Research Organization Cambridge Biomedical
October 22, 2019BioAgilytix Receives Certificate of Registration from CLIA
May 9, 2018Evaluating the Immunogenicity of Antibody–drug Conjugates
April 16, 2018Strategies for Development and Validation of Neutralizing Antibody Assays Supporting Biosimilars
Services
Platforms
